Bufalin suppresses ovarian cancer cell proliferation via EGFR pathway  

作　　者：Lei Dou Dan Zou Feiran Song Yuxin Jin Yin Li Yi Zhang 

机构地区：[1]Department of Gynecology,The First Affiliated Hospital of China Medical University,Shenyang,Liaoning 110001,China [2]First Laboratory of Cancer Institute,The First Affiliated Hospital of China Medical University,Shenyang,Liaoning 110001,China [3]Department of Integration of Chinese and Western Medicine,School of Basic Medical Sciences,Peking University,Beijing 100191,China

出　　处：《Chinese Medical Journal》2022年第4期456-461,共6页中华医学杂志（英文版）

基　　金：This study was supported by a grant from the Special project for central guidance of local science and technology development of Liaoning province(No.2019JH6/10400006)。

摘　　要：Background:Previous studies have shown that bufalin exerts antitumor effects through various mechanisms.This study aimed to determine the antineoplastic mechanism of bufalin,an extract of traditional Chinese medicine toad venom,in ovarian cancer.Methods:The 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide(MTT),5-ethynyl-2′-deoxyuridine(EdU),and colony formation assays were used to investigate the antiproliferative effect of bufalin on the ovarian cancer cell line SK-OV-3.Molecular docking was used to investigate the combination of bufalin and epidermal growth factor receptor(EGFR)protein.Western blotting was performed to detect the expression of EGFR protein and its downstream targets.Results:Bufalin inhibited the proliferation of SK-OV-3 cells in a dose-and time-dependent manner.Bufalin was confirmed to combine with EGFR protein using molecular docking and downregulate expression of EGFR.Bufalin inhibited phosphorylation of EGFR,protein kinase B(AKT),and extracellular signal-regulated kinase(ERK).Conclusion:Bufalin suppresses the proliferation of ovarian cancer cells through the EGFR/AKT/ERK signaling pathway.

关 键 词：BUFALIN Ovarian cancer Epidermal growth factor receptor 

分 类 号：R285[医药卫生—中药学]